An editorial arguing that biotech commercialization should be run the way engineering is run, with specifications, measurement, and repeatable process, rather than treated as a series of one-off translational events.
The piece is indexed under artificial intelligence, biotechnology, commercialization, continuous glucose monitoring, diabetes technology, and translational science. The full text is under publisher embargo until August 2027 and is available at the DOI.